receptor activity modifying protein 1Genealiases: []
Q-omics provides the consensus-scored RAMP1 profile across patient tissues and cancer cell-line models. RAMP1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RAMP1 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, RAMP1 RNA expression shows 15,029 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, BLCA, and TGCT as cancer lineages where RAMP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAMP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAMP1 survival associations across molecular data types. RAMP1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAMP1 RNA expression–survival associations across cancer types. High RAMP1 expression shows unfavorable associations in STAD, UVM, COAD, KIRP and READ, but favorable associations in BRCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for RAMP1 RNA expression.
This table summarizes RAMP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RAMP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAMP1 shows lower tumor expression in BLCA, KICH, KIRC and KIRP and higher tumor expression in THCA and LUAD. The BLCA box plot shows higher RAMP1 RNA expression in normal versus tumor tissue (log2 FC = −4.528, t-test p < 0.001).
This table shows molecular features associated with RAMP1 in patient tissues and cancer cell lines. In patient samples, RAMP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RAMP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
